In addition, the findings of Scott J. Rodig et al. are consistent with those of Douglas B. Johnson et al. They found that melanoma MHC class II expression was associated with a better prognosis in patients initially treated with anti-PD-1 [42]. This evidence concerns the gene HLA-C and melanoma.